Trial Search Results

Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

Three month treatment of acute VTE with Fragmin in pediatric cancer patients

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Stanford Investigator(s):

Intervention(s):

  • Drug: dalteparin

Phase:

Phase 2

Eligibility


Inclusion Criteria:

-

Exclusion Criteria:

-

Ages Eligible for Study

N/A - 18 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting